Research Progress of Immune Checkpoint Therapy on Colorectal Cancer
10.3971/j.issn.1000-8578.2021.20.1060
- VernacularTitle:结直肠癌免疫检查点治疗的研究进展
- Author:
Qihua CAO
1
;
Yanbo XU
;
Dong XU
Author Information
1. Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
- Publication Type:Research Article
- Keywords:
Colorectal cancer;
Immunotherapy;
Immune checkpoint inhibitors
- From:
Cancer Research on Prevention and Treatment
2021;48(3):229-233
- CountryChina
- Language:Chinese
-
Abstract:
At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer, melanoma, bladder cancer and other tumor species, and its treatment methods are also diverse, including tumor vaccine treatment, adoptive T cell therapy, immune checkpoint inhibitor treatment, etc, but current immunotherapy for colorectal cancer mainly focuses on immune checkpoint inhibitors (PD-1/PD-L1 and CTLA-4 inhibitors). Since PD-1/PD-L1 inhibitors have shown amazing efficacy in patients with dMMR/MSI-H advanced colorectal cancer, immune checkpoint inhibitors have gained more and more attention in the field of colorectal cancer, and the treatment options have gradually shifted from late line treatment to first-line treatment or neoadjuvant therapy, and have achieved success. This paper summarizes the research progress of immune checkpoint therapy on colorectal cancer.
